Key Market Indicators
The Czech Republic's expenditure on pharmaceutical research and development is projected to climb to approximately $125 million in purchasing power parity (PPP) by 2028, up from around $112 million in 2023. This growth represents an average annual increase of 1.7%. Since 2010, the nation's pharmaceutical supply has seen a modest uptick of 0.1% per year. In the global ranking for 2023, the Czech Republic held the 13th position. Israel surpassed the Czech Republic with an expenditure also recorded at roughly $112 million PPP. Leading the rankings were China, Germany, and South Korea, securing the second, third, and fourth spots, respectively.
